Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rAAV9-GFP is a research-grade recombinant adeno-associated virus serotype 9 (rAAV9) vector that encodes green fluorescent protein (GFP), typically driven by a constitutive promoter such as CMV (cytomegalovirus). It is a widely utilized gene therapy research tool used to study vector distribution, transduction efficiency, and cellular tropism in various tissues, including the brain, spinal cord, kidney, and liver. In preclinical studies, rAAV9-GFP serves as a reporter construct, allowing researchers to visualize successfully transduced cells via fluorescence microscopy. It is frequently employed as a control or pilot vector in animal models (such as mice, rats, and non-human primates) to optimize delivery strategies for therapeutic gene candidates. This tool is produced by various research suppliers and is not associated with a specific pharmaceutical company as a commercial drug candidate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rAAV9-GFP.